Literature DB >> 15587822

[Cervical cancer. Current view of its epidemiology and risk factors].

Alfonso Torres Lobatón1, Guadalupe Rojo Herrera, Alfonso Torres Rojo, Gabino Hurtado Estrada, Edgar Román Bassaure.   

Abstract

An epidemiologic analysis and a global evaluation of risk factors related to the etiopathogenesis of cervical cancer are reported here. Cervical cancer is the second cause of female malignancies worldwide and represents a health problem in some countries of Africa and Latin America like Haiti, Zimbabwe, Bolivia and Ecuador, with incidence rates from 44.2 to 93.9 per 100,000. Highest death rates are reported in Haiti, Nicaragua, Ecuador and Mexico (53.5 to 17.1 per 100,000, respectively). Although at this time in Mexico it has been reported a 55.4% of early tumors and a decrease of 20% in death rates, in this country cervical cancer is the main cause of death for women malignancies. Sexual activity and parity before 18 years old, human papilloma virus infection (HPV) and some nutritional deficiencies mainly related with antioxidants agents, are in these countries the most important risk factors. Mexican investigations have showed oncogenic HPV genotypes in 80% of aceto white lesions of the cervix, a 50% of HPV16 genome in cervical carcinomas and a variety of HPV16 infection, named HPV16AA-c. Women infected with these viruses, are younger and have more aggressive carcinomas.

Entities:  

Mesh:

Year:  2004        PMID: 15587822

Source DB:  PubMed          Journal:  Ginecol Obstet Mex        ISSN: 0300-9041


  4 in total

1.  Comparisons of 5-aminolevulinic acid photodynamic therapy and after-loading radiotherapy in vivo in cervical cancer.

Authors:  T Gui; Y Wang; Y Mao; J Liu; S Sun; D Cao; J Yang; K Shen
Journal:  Clin Transl Oncol       Date:  2012-10-02       Impact factor: 3.405

2.  Heparin (GAG-hed) inhibits LCR activity of human papillomavirus type 18 by decreasing AP1 binding.

Authors:  Rita Villanueva; Néstor Morales-Peza; Irma Castelán-Sánchez; Enrique García-Villa; Rocio Tapia; Angel Cid-Arregui; Alejandro García-Carrancá; Esther López-Bayghen; Patricio Gariglio
Journal:  BMC Cancer       Date:  2006-08-31       Impact factor: 4.430

3.  Clinical response to glycyrrhizinic acid in genital infection due to human papillomavirus and low-grade squamous intraepithelial lesion.

Authors:  Marcelino Hernández Valencia; Adia Carrillo Pacheco; Tomás Hernández Quijano; Antonio Vargas Girón; Carlos Vargas López
Journal:  Clin Pract       Date:  2011-11-08

Review 4.  High dose rate versus low dose rate intracavity brachytherapy for locally advanced uterine cervix cancer.

Authors:  Ruifeng Liu; XiaoHu Wang; Jin Hui Tian; KeHu Yang; Jun Wang; Lei Jiang; Xiang Yong Hao
Journal:  Cochrane Database Syst Rev       Date:  2014-10-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.